Paul Henderson, Ph.D.

Paul T. Henderson, Ph.D.




Internal Medicine


Internal Medicine


  • Adjunct Professor


Clinical Interests

Mechanisms of cellular response to oxidative stress, drug and carcinogen metabolism, pharmacokinetics assay development, mass spectrometry, HPLC. Dr. Henderson is pursuing the development of advanced diagnostics with the goal of predicting patient response to cancer drugs prior to initiation of toxic chemotherapy. The diagnostics development is enabled by accelerator mass spectrometry (AMS), an ultrasensitive technology for detecting rare isotopes such as radiocarbon and tritium in biological samples. AMS is also useful for measuring pharmacokinetics of small drug doses in humans, which Dr. Henderson is applying to drug development and drug formulation studies. Another project involves the incorporation of hydrophobic drugs and membrane proteins into nanoparticles made of apolipoproteins and phospholipids called nanolipoproitein particles (NLPs). NLPs closely mimic the cellular membrane bilayer, and render hydrophobic molecules water soluble. Dr. Henderson is using NLPs for drug delivery and protein biochemistry studies that are related to breast cancer research.


Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center


Ph.D., Georgia Institute of Technology, Atlanta, Georgia, 1999

B.S., University of Florida, Gainesville, Florida, 1992

Professional Memberships

American Association for Advancement of Science

American Association for Cancer Research

American Chemical Society

Environmental Mutagen Society

Select Recent Publications

For a comprehensive list of Dr. Henderson's publications, please click here (opens new window).